AR-V7 detection guides treatment
AR-V7 detection guides treatment, Published online: 17 July 2018; doi:10.1038/s41571-018-0072-5AR-V7 detection guides treatment (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 17, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Frontline immunotherapy for NSCLC: alone or not alone?
Frontline immunotherapy for NSCLC: alone or not alone?, Published online: 11 July 2018; doi:10.1038/s41571-018-0070-7Platinum-based chemotherapy has long been the mainstay first-line therapy for patients with non-small-cell lung cancer without a targetable driver mutation, but has limited effectiveness. Immunotherapy is drastically changing the treatment landscape for this group and improving survival outcomes, with focus turning to frontline immunotherapy combinations. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 11, 2018 Category: Cancer & Oncology Authors: Cesare Gridelli Francesca Casaluce Source Type: research
Sequencing cells of the immune TME
Sequencing cells of the immune TME, Published online: 09 July 2018; doi:10.1038/s41571-018-0069-0Sequencing cells of the immune TME (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 9, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Redefining KRAS activation
Redefining <i>KRAS</i> activation, Published online: 09 July 2018; doi:10.1038/s41571-018-0068-1Redefining KRAS activation (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 9, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Sodium thiosulfate halves the risk of cisplatin-induced hearing loss
Sodium thiosulfate halves the risk of cisplatin-induced hearing loss, Published online: 06 July 2018; doi:10.1038/s41571-018-0067-2Sodium thiosulfate halves the risk of cisplatin-induced hearing loss (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 6, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Reinforcing the social compromise of accelerated approval
Reinforcing the social compromise of accelerated approval, Published online: 03 July 2018; doi:10.1038/s41571-018-0066-3Accelerated approval enables investigational drugs to reach the US market on the basis of their demonstrated effects in unvalidated surrogate measures, only reasonably likely to predict clinical response. To fulfil the social compromise, regulators should ensure that confirmatory trials testing clinically meaningful end points are already underway at the time of approval. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 3, 2018 Category: Cancer & Oncology Authors: Bishal Gyawali Aaron S. Kesselheim Source Type: research
Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection
Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection, Published online: 03 July 2018; doi:10.1038/s41571-018-0058-3Liquid biopsy approaches hold great promise in early cancer diagnosis or minimal residual disease monitoring for cancer recurrence. Herein, the authors evaluate contemporary next-generation sequencing approaches to circulating tumour DNA detection in these contexts, with a focus on studies in patients with non-small-cell lung cancer. They discuss the feasibility of introducing these strategies into the clinic, highlighting the technical and analytical challenges, as well as ...
Source: Nature Clinical Practice Oncology - July 3, 2018 Category: Cancer & Oncology Authors: Christopher Abbosh Nicolai J. Birkbak Charles Swanton Source Type: research
Cytoreductive nephrectomy in metastatic renal cancer — less is more
Cytoreductive nephrectomy in metastatic renal cancer — less is more, Published online: 02 July 2018; doi:10.1038/s41571-018-0065-4CARMENA, a trial comparing the efficacy of sunitinib alone to that of nephrectomy followed by sunitinib in patients with primary metastatic renal cell carcinoma who require targeted therapy has demonstrated the non-inferiority of systemic therapy alone. The data provided by this and other studies argue for a lesser role of surgery in the management of these patients. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 2, 2018 Category: Cancer & Oncology Authors: Axel Bex John Haanen Source Type: research
SLFN11: a new synthetic lethal target?
SLFN11: a new synthetic lethal target?, Published online: 29 June 2018; doi:10.1038/s41571-018-0064-5SLFN11: a new synthetic lethal target? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 29, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?, Published online: 28 June 2018; doi:10.1038/s41571-018-0055-6Following the success of poly(ADP-ribose) PARP inhibitors in patients with BRCA1/2 mutations, considerable research interest has emerged in the discovery of alternative forms of synthetic lethality. In this Review, the authors summarize the potential of various novel forms of synthetic lethality to further improve the treatment of patients with cancer. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 28, 2018 Category: Cancer & Oncology Authors: Alan Ashworth Christopher J. Lord Source Type: research
Reply to ‘Response to proposal for a novel cancer drug pricing model’
Reply to ‘Response to proposal for a novel cancer drug pricing model’, Published online: 28 June 2018; doi:10.1038/s41571-018-0063-6Reply to ‘Response to proposal for a novel cancer drug pricing model’ (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 28, 2018 Category: Cancer & Oncology Authors: Carin A. Uyl-de Groot Bob L öwenberg Source Type: research
Response to proposal for a novel cancer drug pricing model
Response to proposal for a novel cancer drug pricing model, Published online: 28 June 2018; doi:10.1038/s41571-018-0062-7Response to proposal for a novel cancer drug pricing model (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 28, 2018 Category: Cancer & Oncology Authors: Toon van der Gronde Hubertus G. Leufkens Toine Pieters Source Type: research
Quizartinib tested in patients with high-risk AML
Quizartinib tested in patients with high-risk AML, Published online: 22 June 2018; doi:10.1038/s41571-018-0061-8Quizartinib tested in patients with high-risk AML (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 22, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Ribociclib effective in HR+, HER2– breast cancer
Ribociclib effective in HR<sup>+</sup>, HER2<sup>–</sup> breast cancer, Published online: 21 June 2018; doi:10.1038/s41571-018-0059-2Ribociclib effective in HR+, HER2– breast cancer (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 21, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
PARP inhibitors synergize with abiraterone
PARP inhibitors synergize with abiraterone, Published online: 21 June 2018; doi:10.1038/s41571-018-0060-9PARP inhibitors synergize with abiraterone (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 21, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
